Search

Your search keyword '"Phillips, Andrew N."' showing total 1,710 results
Start Over Author "Phillips, Andrew N."
1,710 results on '"Phillips, Andrew N."'

1. Health workforce needs in Malawi: analysis of the Thanzi La Onse integrated epidemiological model of care

Author

She, Bingling, Mangal, Tara D., Prust, Margaret L., Heung, Stephanie, Chalkley, Martin, Colbourn, Tim, Collins, Joseph H., Graham, Matthew M., Jewell, Britta, Joshi, Purava, Li Lin, Ines, Mnjowe, Emmanuel, Mohan, Sakshi, Molaro, Margherita, Phillips, Andrew N., Revill, Paul, Smith, Robert Manning, Tamuri, Asif U., Twea, Pakwanja D., Manthalu, Gerald, Mfutso-Bengo, Joseph, and Hallett, Timothy B.

Published
2024
Full Text
View/download PDF

3. Estimates of resource use in the public-sector health-care system and the effect of strengthening health-care services in Malawi during 2015–19: a modelling study (Thanzi La Onse)

Author

Hallett, Timothy B, Mangal, Tara D, Tamuri, Asif U, Arinaminpathy, Nimalan, Cambiano, Valentina, Chalkley, Martin, Collins, Joseph H, Cooper, Jonathan, Gillman, Matthew S, Giordano, Mosè, Graham, Matthew M, Graham, William, Hawryluk, Iwona, Janoušková, Eva, Jewell, Britta L, Lin, Ines Li, Manning Smith, Robert, Manthalu, Gerald, Mnjowe, Emmanuel, Mohan, Sakshi, Molaro, Margherita, Ng'ambi, Wingston, Nkhoma, Dominic, Piatek, Stefan, Revill, Paul, Rodger, Alison, Salmanidou, Dimitra, She, Bingling, Smit, Mikaela, Twea, Pakwanja D, Colbourn, Tim, Mfutso-Bengo, Joseph, and Phillips, Andrew N

Published
2025
Full Text
View/download PDF

4. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19

Author

Barkauskas, Christina, Mylonakis, Eleftherios, Poulakou, Garyfallia, Young, Barnaby E, Vock, David M, Siegel, Lianne, Engen, Nicole, Grandits, Greg, Mosaly, Nilima R, Vekstein, Andrew M, Rogers, Ralph, Shehadeh, Fadi, Kaczynski, Matthew, Mylona, Evangelia K, Syrigos, Konstantinos N, Rapti, Vasiliki, Lye, David C, Hui, Diong Shiau, Leither, Lindsay, Knowlton, Kirk U, Jain, Mamta K, Marines-Price, Rubria, Osuji, Alice, Overcash, J Scott, Kalomenidis, Ioannis, Barmparessou, Zafeiria, Waters, Michael, Zepeda, Karla, Chen, Peter, Torbati, Sam, Kiweewa, Francis, Sebudde, Nicholus, Almasri, Eyad, Hughes, Alyssa, Bhagani, Sanjay R, Rodger, Alison, Sandkovsky, Uriel, Gottlieb, Robert L, Nnakelu, Eriobu, Trautner, Barbara, Menon, Vidya, Lutaakome, Joseph, Matthay, Michael, Robinson, Philip, Protopapas, Konstantinos, Koulouris, Nikolaos, Kimuli, Ivan, Baduashvili, Amiran, Braun, Dominique L, Günthard, Huldrych F, Ramachandruni, Srikanth, Kidega, Robert, Kim, Kami, Hatlen, Timothy J, Phillips, Andrew N, Murray, Daniel D, Jensen, Tomas O, Padilla, Maria L, Accardi, Evan X, Shaw-Saliba, Katy, Dewar, Robin L, Teitelbaum, Marc, Natarajan, Ven, Laverdure, Sylvain, Highbarger, Helene C, Rehman, M Tauseef, Vogel, Susan, Vallée, David, Crew, Page, Atri, Negin, Schechner, Adam J, Pett, Sarah, Hudson, Fleur, Badrock, Jonathan, Touloumi, Giota, Brown, Samuel M, Self, Wesley H, North, Crystal M, Ginde, Adit A, Chang, Christina C, Kelleher, Anthony, Nagy-Agren, Stephanie, Vasudeva, Shikha, Looney, David, Nguyen, Hien H, Sánchez, Adriana, Weintrob, Amy C, Grund, Birgit, Sharma, Shweta, Reilly, Cavan S, Paredes, Roger, Bednarska, Agnieszka, Gerry, Norman P, Babiker, Abdel G, Davey, Victoria J, Gelijns, Annetine C, Higgs, Elizabeth S, Kan, Virginia, Matthews, Gail, and Thompson, B Taylor

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Lung, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Adult, Designed Ankyrin Repeat Proteins, Double-Blind Method, Humans, Recombinant Fusion Proteins, SARS-CoV-2, Treatment Outcome, COVID-19 Drug Treatment, ACTIV-3/TICO Study Group, Clinical Sciences, Public Health and Health Services
Abstract

BackgroundEnsovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.ObjectiveTo investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.DesignDouble-blind, randomized, placebo-controlled, clinical trial. (ClinicalTrials.gov: NCT04501978).SettingMultinational, multicenter trial.ParticipantsAdults hospitalized with COVID-19.InterventionIntravenous ensovibep, 600 mg, or placebo.MeasurementsEnsovibep was assessed for early futility on the basis of pulmonary ordinal scores at day 5. The primary outcome was time to sustained recovery through day 90, defined as 14 consecutive days at home or place of usual residence after hospital discharge. A composite safety outcome that included death, serious adverse events, end-organ disease, and serious infections was assessed through day 90.ResultsAn independent data and safety monitoring board recommended that enrollment be halted for early futility after 485 patients were randomly assigned and received an infusion of ensovibep (n = 247) or placebo (n = 238). The odds ratio (OR) for a more favorable pulmonary outcome in the ensovibep (vs. placebo) group at day 5 was 0.93 (95% CI, 0.67 to 1.30; P = 0.68; OR > 1 would favor ensovibep). The 90-day cumulative incidence of sustained recovery was 82% for ensovibep and 80% for placebo (subhazard ratio [sHR], 1.06 [CI, 0.88 to 1.28]; sHR > 1 would favor ensovibep). The primary composite safety outcome at day 90 occurred in 78 ensovibep participants (32%) and 70 placebo participants (29%) (HR, 1.07 [CI, 0.77 to 1.47]; HR

Published
2022

5. Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study

Author

Phillips, Andrew N, Bershteyn, Anna, Revill, Paul, Bansi-Matharu, Loveleen, Kripke, Katharine, Boily, Marie-Claude, Martin-Hughes, Rowan, Johnson, Leigh F, Mukandavire, Zindoga, Jamieson, Lise, Meyer-Rath, Gesine, Hallett, Timothy B, Brink, Debra ten, Kelly, Sherrie L, Nichols, Brooke E, Bendavid, Eran, Mudimu, Edinah, Taramusi, Isaac, Smith, Jennifer, Dalal, Shona, Baggaley, Rachel, Crowley, Siobhan, Terris-Prestholt, Fern, Godfrey-Faussett, Peter, Mukui, Irene, Jahn, Andreas, Case, Kelsey K, Havlir, Diane, Petersen, Maya, Kamya, Moses, Koss, Catherine A, Balzer, Laura B, Apollo, Tsitsi, Chidarikire, Thato, Mellors, John W, Parikh, Urvi M, Godfrey, Catherine, Cambiano, Valentina, and Consortium, HIV Modelling

Subjects
Cost Effectiveness Research, Mental Health, Clinical Research, Prevention, HIV/AIDS, Infectious Diseases, Infection, Good Health and Well Being, Adult, Anti-HIV Agents, Cost-Benefit Analysis, Epidemics, Female, HIV Infections, Humans, Male, Pre-Exposure Prophylaxis, HIV Modelling Consortium, Medical and Health Sciences
Abstract

BackgroundApproaches that allow easy access to pre-exposure prophylaxis (PrEP), such as over-the-counter provision at pharmacies, could facilitate risk-informed PrEP use and lead to lower HIV incidence, but their cost-effectiveness is unknown. We aimed to evaluate conditions under which risk-informed PrEP use is cost-effective.MethodsWe applied a mathematical model of HIV transmission to simulate 3000 setting-scenarios reflecting a range of epidemiological characteristics of communities in sub-Saharan Africa. The prevalence of HIV viral load greater than 1000 copies per mL among all adults (HIV positive and negative) varied from 1·1% to 7·4% (90% range). We hypothesised that if PrEP was made easily available without restriction and with education regarding its use, women and men would use PrEP, with sufficient daily adherence, during so-called seasons of risk (ie, periods in which individuals are at risk of acquiring infection). We refer to this as risk-informed PrEP. For each setting-scenario, we considered the situation in mid-2021 and performed a pairwise comparison of the outcomes of two policies: immediate PrEP scale-up and then continuation for 50 years, and no PrEP. We estimated the relationship between epidemic and programme characteristics and cost-effectiveness of PrEP availability to all during seasons of risk. For our base-case analysis, we assumed a 3-monthly PrEP cost of US$29 (drug $11, HIV test $4, and $14 for additional costs necessary to facilitate education and access), a cost-effectiveness threshold of $500 per disability-adjusted life-year (DALY) averted, an annual discount rate of 3%, and a time horizon of 50 years. In sensitivity analyses, we considered a cost-effectiveness threshold of $100 per DALY averted, a discount rate of 7% per annum, the use of PrEP outside of seasons of risk, and reduced uptake of risk-informed PrEP.FindingsIn the context of PrEP scale-up such that 66% (90% range across setting-scenarios 46-81) of HIV-negative people with at least one non-primary condomless sex partner take PrEP in any given period, resulting in 2·6% (0·9-6·0) of all HIV negative adults taking PrEP at any given time, risk-informed PrEP was predicted to reduce HIV incidence by 49% (23-78) over 50 years compared with no PrEP. PrEP was cost-effective in 71% of all setting-scenarios, and cost-effective in 76% of setting-scenarios with prevalence of HIV viral load greater than 1000 copies per mL among all adults higher than 2%. In sensitivity analyses with a $100 per DALY averted cost-effectiveness threshold, a 7% per year discount rate, or with PrEP use that was less well risk-informed than in our base case, PrEP was less likely to be cost-effective, but generally remained cost-effective if the prevalence of HIV viral load greater than 1000 copies per mL among all adults was higher than 3%. In sensitivity analyses based on additional setting-scenarios in which risk-informed PrEP was less extensively used, the HIV incidence reduction was smaller, but the cost-effectiveness of risk-informed PrEP was undiminished.InterpretationUnder the assumption that making PrEP easily accessible for all adults in sub-Saharan Africa in the context of community education leads to risk-informed use, PrEP is likely to be cost-effective in settings with prevalence of HIV viral load greater than 1000 copies per mL among all adults higher than 2%, suggesting the need for implementation of such approaches, with ongoing evaluation.FundingUS Agency for International Development, US President's Emergency Plan for AIDS Relief, and Bill & Melinda Gates Foundation.

Published
2022

7. Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis

Author

Phillips, Andrew N, Bansi-Matharu, Loveleen, Shahmanesh, Maryam, Hargreaves, James R, Smith, Jennifer, Revill, Paul, Sibanda, Euphemia, Ehrenkranz, Peter, Sikwese, Kenly, Rodger, Alison, Lundgren, Jens D, Gilks, Charles F, Godfrey, Catherine, Cowan, Frances, and Cambiano, Valentina

Published
2023
Full Text
View/download PDF

8. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

Author

Tierney, John, Vogel, Susan E., McNay, Laura A., Cahill, Kelly, Crew, Page, Sardana, Ratna, Segal Raim, Sharo, Shaw-Saliba, Katy, Atri, Negin, Miller, Mark, Vallee, David, Chung, Lucy, Delph, Yvette, Adam, Stacey J., Read, Sarah, Draghia-Akli, Ruxandra, Harrigan, Rachel, Carlsen, Amy, Carter, Anita, DuChene, Alain, Eckroth, Kate, Frase, Alex, Harrison, Merrie, Meger, Sue, Quan, Kien, Quan, Siu Fun, Reilly, Cavan, Thompson, Greg, Walski, Jamie, Moskowitz, Alan J., Bagiella, Emilia, Moquete, Ellen, O'Sullivan, Karen, Marks, Mary E., Accardi, Evan, Kinzel, Emily, Bedoya, Gabriela, Gupta, Lopa, Overbey, Jessica R., Padillia, Maria L., Santos, Milerva, Gillinov, Marc A., Miller, Marissa A., Taddei-Peters, Wendy C., Fenton, Kathleen, Smith, Peter K., Vekstein, Andrew M., Ko, Emily R., Al-Hegelan, Mashael S., McGowan, Lauren M., Motta, Mary, Howell, Shauna, Bent, Francine, Kalager, Rachel, Chan, Emmanuel, Aloor, Heather L., Griffin, S. Michelle, Covington, Anna, McLendon-Arvik, Beth, Bussadori, Barbara, Miller-Bell, Mary, Sampey, Cathy, Gaver, Vincent, Hollister, Beth A., Giangiacomo, Dana M., Pauley, Alena, Patel, Aashay, Classon, Chris, Frazier, Madison, Osborne, Robyn, Conlon, Debbi H., Joshi, Marybeth, Gottlieb, Robert L., Mack, Michael, Berhe, Mezgebe, Haley, Clinton, Dishner, Emma, Bettacchi, Christopher, Golden, Kevin, Duhaime, Erin, Ryan, Madison, Tallmadge, Catherine, Estrada, Lorie, Jones, Felecia, Villa, Samantha, Wang, Samantha, Robert, Raven, Coleman, Tanquinisha, Clariday, Laura, Baker, Rebecca, Hurutado-Rodriguez, Mariana, Iram, Nazia, Fresnedo, Michelle, Davis, Allyson, Leonard, Kiara, Ramierez, Noelia, Thammavong, Jon, Duque, Krizia, Turner, Emma, Fisher, Tammy, Robinson, Dianna, Ransom, Desirae, Maldonado, Nicholas, Lusk, Erica, Killian, Aaron, Palacios, Adriana, Solis, Edilia, Jerrow, Janet, Watts, Matthew, Whitacre, Heather, Cothran, Elizabeth, Bender, William, Miller, Jeffrey, Nugent, Katherine, Farrington, Woodrow, Baio, Kim T., McBride, Mary K., Fielding, Michele, Mathewson, Sonya, Porte, Kristina, Haley, Elizabeth, Rogers, Susan, Tyler, Derrick, Perin, Emerson, Costello, Briana, Postalian, Alexander, Sohail, Rizwan, Hinsu, Punit, Watson, Carolyn, Kappenman, Casey, Chen, James, Walker, Kim, Fink, Melyssa, Phillip, Gabrielle, Mahon, Kim, Sturgis, Lydia, Maher, Patrick, Rogers, Linda, Ng, Nicole, Marshall, Jason, Bassily-Marcus, Adel, Cohen, Ivy, Ramoo, Shamini, Malhotra, Aryan, Kessler, Jonathan, Goetz, Rebekah, Badhwar, Vinay, Hayanga, Jeremiah, Giblin Sutton, Lisa, Williams, Roger, Berry Bartolo, Elizabeth, Walker, Dmitry, Bunner, Robin, Glaze, Chad, Aucremanne, Tanja, Bishop, James, Kelley, Macey, Peterson, Autumn, Sauerborn, Erica, Reckart, Robin, Miller, Brittany, Mittel, Aaron, Darmanian, Anita, Rosen, Amanda, Madahar, Purnema, Schicchi, John, Gosek, Katarzyna, Dzierba, Amy, Wahab, Romina, Eng, Connie, Al-Saadi, Mukhtar, Zahiruddin, Faisal, Syed, Mohi, George, Michael, Patel, Varsha, Onwunyi, Chisom, Barroso da Costa, Rosa, North, Crystal, Ringwood, Nancy, Fitzgerald, Laura, Muzikansky, Ariela, Morse, Richard, Brower, Roy G., Reineck, Lora A., Bienstock, Karen, Hou, Peter, Steingrub, Jay S., Tidswell, Mark A., Kozikowski, Lori-Ann, Kardos, Cynthia, De Souza, Leslie, Talmor, Daniel, Shapiro, Nathan, Hibbert, Kathryn, Brait, Kelsey, Kone, Mamary, Hendey, Gregory, Kangelaris, Kirsten N., Ashktorab, Kimia, Gropper, Rachel, Agrawal, Anika, Timothy, Kelly, Zhou, Hanjing, Hughes, Alyssa, Garcia, Rebekah, Torres, Adrian, Hernandez-Almaraz, Maria Elena, Vojnik, Rosemary, Perez, Cynthia, McDowell, Jordan, Chang, Steven Y., Vargas, Julia, Moss, Marc, McKeehan, Jeffrey, Higgins, Carrie, Johnson, Emily, Slaughter, Suzanne, Wyles, David, Hiller, Terra, Oakes, Judy, Garcia, Ana, Gravitz, Stephanie, Lyle, Carolynn, Swanson, Diandra, Gong, Michelle Ng., Richardson, Lynnne D., Chen, Jen-Ting, Moskowitz, Ari, Mohamed, Amira, Lopez, Brenda, Amosu, Omowunmi, Tzehaie, Hiwet, Boujid, Sabah, Bixby, Billie, Lopez, Anitza A., Durley, JaVon, Gilson, Boris, Hite, R. Duncan, Wang, Henry, Wiedemann, Hebert P., Mehkri, Omar, Ashok, Kiran, King, Alexander, Brennan, Connery, Exline, Matthew C., Englert, Joshua A., Karow, Sarah, Schwartz, Elizabeth, So, Preston, So, Madison, Krol, Olivia F., Briceno Parra, Genesis I., Mills, Emmanuel Nii Lantei, Oh, Minn, Pena, Jose, Martínez, Jesús Alejandro, Jackman, Susan E., Bayoumi, Emad, Pascual, Ethan, Caudill, Antonina, Chen, Po-En, Richardson, Tabia, Clapham, Gregg J., Herrera, Lisa, Ojukwu, Cristabelle, Fine, Devin, Gomez, Millie J., Choi-Kuaea, Yunhee, Weissberg, Gwendolyn, Isip, Katherine, Mattison, Brittany, Tran, Dana, Emilov Dukov, Jennifer, Chung, Paul, Kang, Bo Ran, Escobar, Lauren, Tran, Trung, Baig, Saba, Wallick, Julie A., Duven, Alexandria M., Fletcher, Dakota D., Gundel, Stephanie, Fuentes, Megan, Newton, Maranda, Peterson, Emily, Jiang, Kelsey, Files, D. Clark, Miller, Chadwick, Lematty, Caitlin, Rasberry, April, Warden, Ashley, Bledsoe, Joseph, Knowlton, Kirk, Knox, Daniel B., Klippel, Carolyn, Armbruster, Brent P., Applegate, Darrin, Imel, Karah, Fergus, Melissa, Rahmati, Kasra, Jensen, Hannah, Aston, Valerie T., Jeppson, Joshua, Marshall, J. Hunter, Lumpkin, Jenna, Smith, Cassie, Burke, Tyler, Gray, Andrew, Paine, Robert, Callahan, Sean, Yamane, Misty, Waddoups, Lindsey, Rice, Todd W., Johnson, Jakea, Gray, Christopher, Hays, Margaret, Roth, Megan, Musick, Sarah, Miller, Karen, Semler, Matthew W., Popielski, Laura, Kambo, Amy, Viens, Kimberly, Turner, Melissa, Vjecha, Michael J., Denyer, Rachel, Khosla, Rahul, Rajendran, Bindu, Gonzales, Melissa, Moriarty, Theresa, Biswas, Kousick, Harrington, Cristin, Garcia, Amanda, Bremer, Tammy, Burke, Tara, Koker, Brittany, Pittman, David, Vasudeva, Shikha S., Anholm, James D., Specht, Lennard, Rodriguez, Aimee, Ngo, Han, Duong, Lien, Previte, Matthew, Raben, Dorthe, Nielsen, Charlotte B., Friis Larsen, Jakob, Peters, Lars, Matthews, Gail, Kelleher, Anthony, Polizzotto, Mark, Carey, Catherine, Chang, Christina, Dharan, Nila, Hough, Sally, Virachit, Sophie, Davidson, Sarah, Bice, Daniel J., Ognenovska, Katherine, Cabrera, Gesalit, Flynn, Ruth, Abdelghany, Mazin, Baseler, Beth, Teitelbaum, Marc, Holley, H. Preston, Jankelevich, Shirley, Adams, Amy, Becker, Nancy, Doleny, Suzanne, Hissey, Debbie, Simpson, Shelly, Kim, Mi Ha, Beeler, Joy, Harmon, Liam, Vanderpuye, Sharon, Yeon, Lindsey, Frye, Leanna, Rudzinski, Erin, Buehn, Molly, Eccard-Koons, Vanessa, Frary, Sadie, MacDonalad, Leah, Cash, Jennifer, Hoopengardner, Lisa, Linton, Jessica, Nelson, Michaela, Spinelli-Nadzam, Mary, Proffitt, Calvin, Lee, Christopher, Engel, Theresa, Fontaine, Laura, Osborne, CK, Hohn, Matt, Galcik, Michael, Thompson, DeeDee, Sandrus, Jen, Manchard, Jon, Giri, Jiwan, Kopka, Stacy, Chang, Weizhong, Sherman, Brad T., Rupert, Adam W., Highbarger, Helene, Baseler, Michael, Lallemand, Perrine, Rehman, Tauseef, Imamichi, Tom, Laverdure, Sylvain, Paudel, Sharada, Cook, Kyndal, Haupt, Kendra, Hazen, Allison, Badralmaa, Yunden, Highbarger, Jeroen, McCormack, Ashley, Gerry, Norman P., Smith, Kenneth, Patel, Bhakti, Domeraski, Nadia, Hoover, Marie L., DuChateau, Nadine, Flosi, Adam, Nelson, Rich, Stojanovic, Jelena, Wenner, Christine, Brown, Samuel M, Barkauskas, Christina E, Grund, Birgit, Sharma, Shweta, Phillips, Andrew N, Leither, Lindsay, Peltan, Ithan D, Lanspa, Michael, Gilstrap, Daniel L, Mourad, Ahmad, Lane, Kathleen, Beitler, Jeremy R, Serra, Alexis L, Garcia, Ivan, Almasri, Eyad, Fayed, Mohamed, Hubel, Kinsley, Harris, Estelle S, Middleton, Elizabeth A, Barrios, Macy A G, Mathews, Kusum S, Goel, Neha N, Acquah, Samuel, Mosier, Jarrod, Hypes, Cameron, Salvagio Campbell, Elizabeth, Khan, Akram, Hough, Catherine L, Wilson, Jennifer G, Levitt, Joseph E, Duggal, Abhijit, Dugar, Siddharth, Goodwin, Andrew J, Terry, Charles, Chen, Peter, Torbati, Sam, Iyer, Nithya, Sandkovsky, Uriel S, Johnson, Nicholas J, Robinson, Bryce R H, Matthay, Michael A, Aggarwal, Neil R, Douglas, Ivor S, Casey, Jonathan D, Hache-Marliere, Manuel, Georges Youssef, J, Nkemdirim, William, Leshnower, Brad, Awan, Omar, Pannu, Sonal, O'Mahony, Darragh Shane, Manian, Prasad, Awori Hayanga, J W, Wortmann, Glenn W, Tomazini, Bruno M, Miller, Robert F, Jensen, Jens-Ulrik, Murray, Daniel D, Bickell, Nina A, Zatakia, Jigna, Burris, Sarah, Higgs, Elizabeth S, Natarajan, Ven, Dewar, Robin L, Schechner, Adam, Kang, Nayon, Arenas-Pinto, Alejandro, Hudson, Fleur, Ginde, Adit A, Self, Wesley H, Rogers, Angela J, Oldmixon, Cathryn F, Morin, Haley, Sanchez, Adriana, Weintrob, Amy C, Cavalcanti, Alexandre Biasi, Davis-Karim, Anne, Engen, Nicole, Denning, Eileen, Taylor Thompson, B, Gelijns, Annetine C, Kan, Virginia, Davey, Victoria J, Lundgren, Jens D, Babiker, Abdel G, Neaton, James D, and Lane, H Clifford

Published
2023
Full Text
View/download PDF

9. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study

Author

Smith, Jennifer, Bansi-Matharu, Loveleen, Cambiano, Valentina, Dimitrov, Dobromir, Bershteyn, Anna, van de Vijver, David, Kripke, Katharine, Revill, Paul, Boily, Marie-Claude, Meyer-Rath, Gesine, Taramusi, Isaac, Lundgren, Jens D, van Oosterhout, Joep J, Kuritzkes, Daniel, Schaefer, Robin, Siedner, Mark J, Schapiro, Jonathan, Delany-Moretlwe, Sinead, Landovitz, Raphael J, Flexner, Charles, Jordan, Michael, Venter, Francois, Radebe, Mopo, Ripin, David, Jenkins, Sarah, Resar, Danielle, Amole, Carolyn, Shahmanesh, Maryam, Gupta, Ravindra K, Raizes, Elliot, Johnson, Cheryl, Inzaule, Seth, Shafer, Robert, Warren, Mitchell, Stansfield, Sarah, Paredes, Roger, and Phillips, Andrew N

Published
2023
Full Text
View/download PDF

10. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study

Author

Phillips, Andrew N, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel, Wensing, Annemarie, Lundgren, Jens D, De Luca, Andrea, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Bansi-Matharu, Loveleen, Nakagawa, Fumiyo, Kalua, Thokozani, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Clayden, Polly, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Bertagnolio, Silvia, and Calmy, Alexandra

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Prevention, HIV/AIDS, Pediatric, Aetiology, Evaluation of treatments and therapeutic interventions, 2.2 Factors relating to the physical environment, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Africa South of the Sahara, Antiretroviral Therapy, Highly Active, Developmental Disabilities, Drug Resistance, Viral, Female, HIV Infections, HIV Integrase Inhibitors, Heterocyclic Compounds, 3-Ring, Humans, Male, Middle Aged, Oxazines, Piperazines, Pregnancy, Pyridones, Risk Assessment, Sustained Virologic Response, Treatment Outcome, Viral Load, Young Adult, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThe integrase inhibitor dolutegravir could have a major role in future antiretroviral therapy (ART) regimens in sub-Saharan Africa because of its high potency and barrier to resistance, good tolerability, and low cost, but there is uncertainty over appropriate policies for use relating to the potential for drug resistance spread and a possible increased risk of neural tube defects in infants if used in women at the time of conception. We used an existing individual-based model of HIV transmission, progression, and the effect of ART with the aim of informing policy makers on approaches to the use of dolutegravir that are likely to lead to the highest population health gains.MethodsWe used an existing individual-based model of HIV transmission and progression in adults, which takes into account the effects of drug resistance and differential drug potency in determining viral suppression and clinical outcomes to compare predicted outcomes of alternative ART regimen policies. We calculated disability adjusted life-years (DALYs) for each policy, assuming that a woman having a child with a neural tube defect incurs an extra DALY per year for the remainder of the time horizon and accounting for mother-to-child transmission. We used a 20 year time horizon, a 3% discount rate, and a cost-effectiveness threshold of US$500 per DALY averted.FindingsThe greatest number of DALYs is predicted to be averted with use of a policy in which tenofovir, lamivudine, and dolutegravir is used in all people on ART, including switching to tenofovir, lamivudine, and dolutegravir in those currently on ART, regardless of current viral load suppression and intention to have (more) children. This result was consistent in several sensitivity analyses. We predict that this policy would be cost-saving.InterpretationUsing a standard DALY framework to compare health outcomes from a public health perspective, the benefits of transition to tenofovir, lamivudine, and dolutegravir for all substantially outweighed the risks.FundingBill & Melinda Gates Foundation.

Published
2019

11. Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised controlled trial

Author

Rodger, Alison J, McCabe, Leanne, Phillips, Andrew N, Lampe, Fiona C, Burns, Fiona, Ward, Denise, Delpech, Valerie, Weatherburn, Peter, Witzel, T Charles, Pebody, Roger, Kirwan, Peter, Gabriel, Michelle, Khawam, Jameel, Brady, Michael, Fenton, Kevin A, Trevelion, Roy, Collaco-Moraes, Yolanda, McCormack, Sheena, and Dunn, David

Published
2022
Full Text
View/download PDF

12. Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

Author

Ginde, Adit A., Paredes, Roger, Murray, Thomas A., Engen, Nicole, Grandits, Greg, Vekstein, Andrew, Ivey, Noel, Mourad, Ahmad, Sandkovsky, Uriel, Gottlieb, Robert L., Berhe, Mezgebe, Jain, Mamta K., Marines-Price, Rubria, Agbor Agbor, Barbine Tchamba, Mateu, Lourdes, España-Cueto, Sergio, Lladós, Gemma, Mylonakis, Eleftherios, Rogers, Ralph, Shehadeh, Fadi, Filbin, Michael R., Hibbert, Kathryn A., Kim, Kami, Tran, Thanh, Morris, Peter E., Cassity, Evan P., Trautner, Barbara, Pandit, Lavannya M., Knowlton, Kirk U., Leither, Lindsay, Matthay, Michael A., Rogers, Angela J., Drake, Wonder, Jones, Beatrice, Poulakou, Garyfallia, Syrigos, Konstantinos N., Fernández-Cruz, Eduardo, Natale, Marisa Di, Almasri, Eyad, Balerdi-Sarasola, Leire, Bhagani, Sanjay R., Boyle, Katherine L., Casey, Jonathan D., Chen, Peter, Douin, David J., Files, D. Clark, Günthard, Huldrych F., Hite, R. Duncan, Hyzy, Robert C., Khan, Akram, Kibirige, Moses, Kidega, Robert, Kiweewa, Francis, Jensen, Jens-Ulrik, Leshnower, Bradley G., Lutaakome, Joseph K., Manian, Prasad, Menon, Vidya, Morales-Rull, Jose Luis, O'Mahony, D. Shane, Overcash, J. Scott, Ramachandruni, Srikant, Steingrub, Jay S., Taha, Hassan S., Waters, Michael, Young, Barnaby E., Phillips, Andrew N., Murray, Daniel D., Jensen, Tomas O., Padilla, Maria L., Sahner, David, Shaw-Saliba, Katy, Dewar, Robin L., Teitelbaum, Marc, Natarajan, Ven, Rehman, M. Tauseef, Pett, Sarah, Hudson, Fleur, Touloumi, Giota, Brown, Samuel M., Self, Wesley H., Chang, Christina C., Sánchez, Adriana, Weintrob, Amy C., Hatlen, Timothy, Grund, Birgit, Sharma, Shweta, Reilly, Cavan S., Garbes, Pedro, Esser, Mark T., Templeton, Alison, Babiker, Abdel G., Davey, Victoria J., Gelijns, Annetine C., Higgs, Elizabeth S., Kan, Virginia, Matthews, Gail, Thompson, B. Taylor, Neaton, James D., Lane, H. Clifford, and Lundgren, Jens D.

Published
2022
Full Text
View/download PDF

13. Transmission reduction, health benefits, and upper-bound costs of interventions to improve retention on antiretroviral therapy: a combined analysis of three mathematical models

Author

Bershteyn, Anna, Jamieson, Lise, Kim, Hae-Young, Platais, Ingrida, Milali, Masabho P, Mudimu, Edinah, ten Brink, Debra, Martin-Hughes, Rowan, Kelly, Sherrie L, Phillips, Andrew N, Bansi-Matharu, Loveleen, Cambiano, Valentina, Revill, Paul, Meyer-Rath, Gesine, and Nichols, Brooke E

Published
2022
Full Text
View/download PDF

14. Perspectives on the use of modelling and economic analysis to guide HIV programmes in sub-Saharan Africa

Author

Revill, Paul, Rangaraj, Ajay, Makochekanwa, Albert, Mpofu, Amon, Ciaranello, Andrea L., Jahn, Andreas, Gonani, Andrew, Phillips, Andrew N., Bershteyn, Anna, Zwizwai, Benson, Nichols, Brooke E., Pretorius, Carel, Kerr, Cliff C., Carlson, Cindy, Ten Brink, Debra, Mudimu, Edinah, Kataika, Edward, Lamontagne, Erik, Terris-Prestholt, Fern, Cowan, Frances M., Manthalu, Gerald, Oberth, Gemma, Mayer-Rath, Gesine, Semini, Iris, Taramusi, Isaac, Eaton, Jeffrey W., Zhao, Jinjou, Stover, John, Izazola-Licea, Jose A, Kripke, Katherine, Johnson, Leigh, Bansi-Matharu, Loveleen, Gorgons, Marelize, Morrison, Michelle, Chagoma, Newton, Mugurungi, Owen, Stuart, Robyn M., Martin-Hughes, Rowan, Nyirenda, Rose, Barnabas, Ruanne V., Mohan, Sakshi, Kelly, Sherrie L., Sibandze, Sibusiso, Walker, Simon, Banda, Stephen, Braithwaite, R. Scott, Chidarikire, Thato, Hallett, Timothy B., Kalua, Thoko, Apollo, Tsitsi, and Cambiano, Valentina

Published
2022
Full Text
View/download PDF

15. Mathematical modelling to estimate the impact of maternal and perinatal healthcare services and interventions on health in sub-Saharan Africa: A scoping review.

Author

Collins, Joseph H., Cambiano, Valentina, Phillips, Andrew N., and Colbourn, Tim

Subjects
NEONATAL mortality, MEDICAL care, MATERNAL mortality, SYSTEM dynamics, HEALTH policy
Abstract

Introduction: Mathematical modelling is a commonly utilised tool to predict the impact of policy on health outcomes globally. Given the persistently high levels of maternal and perinatal morbidity and mortality in sub-Saharan Africa, mathematical modelling is a potentially valuable tool to guide strategic planning for health and improve outcomes. Methods: The aim of this scoping review was to explore the characteristics of mathematical models and modelling studies evaluating the impact of maternal and/or perinatal healthcare interventions or services on health-related outcomes in the region. A search across three databases was conducted on 2nd November 2023 which returned 8660 potentially relevant studies, from which 60 were included in the final review. Characteristics of these studies, the interventions which were evaluated, the models utilised, and the analyses conducted were extracted and summarised. Results: Findings suggest that the popularity of modelling within this field is increasing over time with most studies published after 2015 and that population-based, deterministic, linear models were most frequently utilised, with the Lives Saved Tool being applied in over half of the reviewed studies (n = 34, 57%). Much less frequently (n = 6) models utilising system-thinking approaches, such as individual-based modelling or systems dynamics modelling, were developed and applied. Models were most applied to estimate the impact of interventions or services on maternal mortality (n = 34, 57%) or neonatal mortality outcomes (n = 39, 65%) with maternal morbidity (n = 4, 7%) and neonatal morbidity (n = 6, 10%) outcomes and stillbirth reported on much less often (n = 14, 23%). Discussion: Going forward, given that healthcare delivery systems have long been identified as complex adaptive systems, modellers may consider the advantages of applying systems-thinking approaches to evaluate the impact of maternal and perinatal health policy. Such approaches allow for a more realistic and explicit representation of the systems- and individual- level factors which impact the effectiveness of interventions delivered within health systems. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study

Author

Phillips, Andrew N, Cambiano, Valentina, Nakagawa, Fumiyo, Revill, Paul, Jordan, Michael R, Hallett, Timothy B, Doherty, Meg, De Luca, Andrea, Lundgren, Jens D, Mhangara, Mutsa, Apollo, Tsitsi, Mellors, John, Nichols, Brooke, Parikh, Urvi, Pillay, Deenan, de Wit, Tobias Rinke, Sigaloff, Kim, Havlir, Diane, Kuritzkes, Daniel R, Pozniak, Anton, van de Vijver, David, Vitoria, Marco, Wainberg, Mark A, Raizes, Elliot, Bertagnolio, Silvia, and Africa, Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Public Health, Health Sciences, Antimicrobial Resistance, HIV/AIDS, Infectious Diseases, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adolescent, Adult, Africa South of the Sahara, Cost-Benefit Analysis, HIV Infections, HIV Integrase Inhibitors, Health Policy, Heterocyclic Compounds, 3-Ring, Humans, Middle Aged, Models, Economic, Oxazines, Piperazines, Pyridones, Treatment Outcome, Young Adult, Working Group on Modelling Potential Responses to High Levels of Pre-ART Drug Resistance in Sub-Saharan Africa, Medical and Health Sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundThere is concern over increasing prevalence of non-nucleoside reverse-transcriptase inhibitor (NNRTI) resistance in people initiating antiretroviral therapy (ART) in low-income and middle-income countries. We assessed the effectiveness and cost-effectiveness of alternative public health responses in countries in sub-Saharan Africa where the prevalence of pretreatment drug resistance to NNRTIs is high.MethodsThe HIV Synthesis Model is an individual-based simulation model of sexual HIV transmission, progression, and the effect of ART in adults, which is based on extensive published data sources and considers specific drugs and resistance mutations. We used this model to generate multiple setting scenarios mimicking those in sub-Saharan Africa and considered the prevalence of pretreatment NNRTI drug resistance in 2017. We then compared effectiveness and cost-effectiveness of alternative policy options. We took a 20 year time horizon, used a cost effectiveness threshold of US$500 per DALY averted, and discounted DALYs and costs at 3% per year.FindingsA transition to use of a dolutegravir as a first-line regimen in all new ART initiators is the option predicted to produce the most health benefits, resulting in a reduction of about 1 death per year per 100 people on ART over the next 20 years in a situation in which more than 10% of ART initiators have NNRTI resistance. The negative effect on population health of postponing the transition to dolutegravir increases substantially with higher prevalence of HIV drug resistance to NNRTI in ART initiators. Because of the reduced risk of resistance acquisition with dolutegravir-based regimens and reduced use of expensive second-line boosted protease inhibitor regimens, this policy option is also predicted to lead to a reduction of overall programme cost.InterpretationA future transition from first-line regimens containing efavirenz to regimens containing dolutegravir formulations in adult ART initiators is predicted to be effective and cost-effective in low-income settings in sub-Saharan Africa at any prevalence of pre-ART NNRTI resistance. The urgency of the transition will depend largely on the country-specific prevalence of NNRTI resistance.FundingBill & Melinda Gates Foundation, World Health Organization.

Published
2018

18. Estimating the health burden of road traffic injuries in Malawi using an individual-based model

Author

Manning Smith, Robert, Cambiano, Valentina, Colbourn, Tim, Collins, Joseph H., Graham, Matthew, Jewell, Britta, Li Lin, Ines, Mangal, Tara D., Manthalu, Gerald, Mfutso-Bengo, Joseph, Mnjowe, Emmanuel, Mohan, Sakshi, Ng’ambi, Wingston, Phillips, Andrew N., Revill, Paul, She, Bingling, Sundet, Mads, Tamuri, Asif, Twea, Pakwanja D., and Hallet, Timothy B.

Published
2022
Full Text
View/download PDF

19. We carried her in a wheelbarrow to the clinic”: Process evaluation of the AMETHIST intervention combining microplanning with self-help groups to improve HIV prevention and treatment among female sex workers in Zimbabwe

Author

Machingura, Fortunate, primary, Madimutsa, Gracious, additional, Makamba, Memory, additional, Kujeke, Tatenda, additional, Takaruza, Albert, additional, Maguma, Jaspar, additional, Ali, Sanni, additional, Chabata, Sungai T, additional, Matambanadzo, Primrose, additional, Steen, Richard, additional, Shahmanesh, Maryam, additional, Mpofu, Amon, additional, Mugurungi, Owen, additional, Phillips, Andrew N, additional, Hargreaves, James R, additional, Cowan, Frances M, additional, and Busza, Joanna, additional

Published
2024
Full Text
View/download PDF

22. Impact and acceptability of HIV self-testing for trans men and trans women: A mixed-methods subgroup analysis of the SELPHI randomised controlled trial and process evaluation in England and Wales

Author

Witzel, T. Charles, Wright, Talen, McCabe, Leanne, Gabriel, Michelle M., Wolton, Aedan, Gafos, Mitzy, Ward, Denise, Lampe, Fiona C., Phillips, Andrew N., Trevelion, Roy, Collaco-Moraes, Yolanda, Harbottle, Justin, Speakman, Andrew, Bonell, Chris, Dunn, David D., McCormack, Sheena, Burns, Fiona M., Weatherburn, Peter, and Rodger, Alison J.

Published
2021
Full Text
View/download PDF

23. Prospective association of social circumstance, socioeconomic, lifestyle and mental health factors with subsequent hospitalisation over 6–7 year follow up in people living with HIV

Author

Rein, Sophia M., Smith, Colette J, Chaloner, Clinton, Stafford, Adam, Rodger, Alison J., Johnson, Margaret A., McDonnell, Jeffrey, Burns, Fiona, Madge, Sara, Miners, Alec, Sherr, Lorraine, Collins, Simon, Speakman, Andrew, Phillips, Andrew N., and Lampe, Fiona C.

Published
2021
Full Text
View/download PDF

24. A new approach to Health Benefits Package design: an application of the Thanzi La Onse model in Malawi.

Author

Molaro, Margherita, Mohan, Sakshi, She, Bingling, Chalkley, Martin, Colbourn, Tim, Collins, Joseph H., Connolly, Emilia, Graham, Matthew M., Janoušková, Eva, Li Lin, Ines, Manthalu, Gerald, Mnjowe, Emmanuel, Nkhoma, Dominic, Twea, Pakwanja D., Phillips, Andrew N., Revill, Paul, Tamuri, Asif U., Mfutso-Bengo, Joseph, Mangal, Tara D., and Hallett, Timothy B.

Subjects
CONSTRAINED optimization, PACKAGING design, RESOURCE allocation, MORTALITY, MEDICAL care
Abstract

An efficient allocation of limited resources in low-income settings offers the opportunity to improve population-health outcomes given the available health system capacity. Efforts to achieve this are often framed through the lens of "health benefits packages" (HBPs), which seek to establish which services the public healthcare system should include in its provision. Analytic approaches widely used to weigh evidence in support of different interventions and inform the broader HBP deliberative process however have limitations. In this work, we propose the individual-based Thanzi La Onse (TLO) model as a uniquely-tailored tool to assist in the evaluation of Malawi-specific HBPs while addressing these limitations. By mechanistically modelling—and calibrating to extensive, country-specific data—the incidence of disease, health-seeking behaviour, and the capacity of the healthcare system to meet the demand for care under realistic constraints on human resources for health available, we were able to simulate the health gains achievable under a number of plausible HBP strategies for the country. We found that the HBP emerging from a linear constrained optimisation analysis (LCOA) achieved the largest health gain—∼8% reduction in disability adjusted life years (DALYs) between 2023 and 2042 compared to the benchmark scenario—by concentrating resources on high-impact treatments. This HBP however incurred a relative excess in DALYs in the first few years of its implementation. Other feasible approaches to prioritisation were assessed, including service prioritisation based on patient characteristics, rather than service type. Unlike the LCOA-based HBP, this approach achieved consistent health gains relative to the benchmark scenario on a year- to-year basis, and a 5% reduction in DALYs over the whole period, which suggests an approach based upon patient characteristics might prove beneficial in the future. Author summary: All publicly funded healthcare systems face difficult decisions about how limited resources should be allocated to achieve the greatest possible return in health. These decisions are particularly pressing in lower-income countries (LICs) like Malawi, where resources are extremely limited and their inefficient allocation results in larger morbidity and mortality. In this work, we introduce a new analytical tool to inform such decisions based on an "all diseases, whole healthcare system" simulation specifically tailored to Malawi, the Thanzi La Onse (TLO) model. The TLO model is able to forecast the health burden that should be expected from different resource-allocation strategies in Malawi specifically, allowing policy-makers to explore a wide range of policy options in a safe and theoretical fashion. In this analysis, we compare the forecasted health burden from a set of common resource-prioritisation strategies, and draw some general conclusions as to what makes certain strategies more or less effective in reducing the health burden incurred. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Potential effects of disruption to HIV programmes in sub-Saharan Africa caused by COVID-19: results from multiple mathematical models

Author

Jewell, Britta L, Mudimu, Edinah, Stover, John, ten Brink, Debra, Phillips, Andrew N, Smith, Jennifer A, Martin-Hughes, Rowan, Teng, Yu, Glaubius, Robert, Mahiane, Severin Guy, Bansi-Matharu, Loveleen, Taramusi, Isaac, Chagoma, Newton, Morrison, Michelle, Doherty, Meg, Marsh, Kimberly, Bershteyn, Anna, Hallett, Timothy B, and Kelly, Sherrie L

Published
2020
Full Text
View/download PDF

27. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines

Author

Phillips, Andrew N, Bansi-Matharu, Loveleen, Venter, Francois, Havlir, Diane, Pozniak, Anton, Kuritzkes, Daniel R, Wensing, Annemarie, Lundgren, Jens D, Pillay, Deenan, Mellors, John, Cambiano, Valentina, Jahn, Andreas, Apollo, Tsitsi, Mugurungi, Owen, Ripin, David, Da Silva, Juliana, Raizes, Elliot, Ford, Nathan, Siberry, George K, Gupta, Ravindra K, Barnabas, Ruanne, Revill, Paul, Cohn, Jennifer, Calmy, Alexandra, and Bertagnolio, Silvia

Published
2020
Full Text
View/download PDF

28. The 10-year health impact, economic impact, and return on investment of the South African molecular diagnostics programme for HIV, Tuberculosis and SARS-CoV-2

Author

Nichols, Brooke E., primary, de Nooy, Alexandra, additional, Cassim, Naseem, additional, Hans, Lucia, additional, da Silva, Manuel Pedro, additional, Chetty, Kamy, additional, Grantz, Kyra H., additional, Han, Alvin X., additional, Phillips, Andrew N., additional, Jamieson, Lise, additional, Scott, Lesley E., additional, and Stevens, Wendy S., additional

Published
2024
Full Text
View/download PDF

29. Using observational data to emulate a randomized trial of dynamic treatment-switching strategies: an application to antiretroviral therapy

Author

Cain, Lauren E, Saag, Michael S, Petersen, Maya, May, Margaret T, Ingle, Suzanne M, Logan, Roger, Robins, James M, Abgrall, Sophie, Shepherd, Bryan E, Deeks, Steven G, Gill, M John, Touloumi, Giota, Vourli, Georgia, Dabis, François, Vandenhende, Marie-Anne, Reiss, Peter, van Sighem, Ard, Samji, Hasina, Hogg, Robert S, Rybniker, Jan, Sabin, Caroline A, Jose, Sophie, del Amo, Julia, Moreno, Santiago, Rodríguez, Benigno, Cozzi-Lepri, Alessandro, Boswell, Stephen L, Stephan, Christoph, Pérez-Hoyos, Santiago, Jarrin, Inma, Guest, Jodie L, Monforte, Antonella D’Arminio, Antinori, Andrea, Moore, Richard, Campbell, Colin NJ, Casabona, Jordi, Meyer, Laurence, Seng, Rémonie, Phillips, Andrew N, Bucher, Heiner C, Egger, Matthias, Mugavero, Michael J, Haubrich, Richard, Geng, Elvin H, Olson, Ashley, Eron, Joseph J, Napravnik, Sonia, Kitahata, Mari M, Van Rompaey, Stephen E, Teira, Ramón, Justice, Amy C, Tate, Janet P, Costagliola, Dominique, Sterne, Jonathan AC, Hernán, Miguel A, and Systems, and the HIV-CAUSAL Collaboration on behalf of the Antiretroviral Therapy Cohort Collaboration the Centers for AIDS Research Network of Integrated Clinical

Subjects
Epidemiology, Health Sciences, Clinical Research, Infectious Diseases, HIV/AIDS, Sexually Transmitted Infections, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Infection, Good Health and Well Being, Adult, Anti-HIV Agents, CD4 Lymphocyte Count, Female, HIV Infections, HIV-1, Humans, Male, Middle Aged, Observational Studies as Topic, Randomized Controlled Trials as Topic, Survival Analysis, United Kingdom, Viral Load, HIV, antiretroviral therapy, inverse-probability weighting, observational studies, mortality, dynamic strategies, Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems, and the HIV-CAUSAL Collaboration, Statistics, Public Health and Health Services, Public health
Abstract

BackgroundWhen a clinical treatment fails or shows suboptimal results, the question of when to switch to another treatment arises. Treatment switching strategies are often dynamic because the time of switching depends on the evolution of an individual's time-varying covariates. Dynamic strategies can be directly compared in randomized trials. For example, HIV-infected individuals receiving antiretroviral therapy could be randomized to switching therapy within 90 days of HIV-1 RNA crossing above a threshold of either 400 copies/ml (tight-control strategy) or 1000 copies/ml (loose-control strategy).MethodsWe review an approach to emulate a randomized trial of dynamic switching strategies using observational data from the Antiretroviral Therapy Cohort Collaboration, the Centers for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. We estimated the comparative effect of tight-control vs. loose-control strategies on death and AIDS or death via inverse-probability weighting.ResultsOf 43 803 individuals who initiated an eligible antiretroviral therapy regimen in 2002 or later, 2001 met the baseline inclusion criteria for the mortality analysis and 1641 for the AIDS or death analysis. There were 21 deaths and 33 AIDS or death events in the tight-control group, and 28 deaths and 41 AIDS or death events in the loose-control group. Compared with tight control, the adjusted hazard ratios (95% confidence interval) for loose control were 1.10 (0.73, 1.66) for death, and 1.04 (0.86, 1.27) for AIDS or death.ConclusionsAlthough our effective sample sizes were small and our estimates imprecise, the described methodological approach can serve as an example for future analyses.

Published
2016

30. Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa

Author

Phillips, Andrew N, Cambiano, Valentina, Revill, Paul, Nakagawa, Fumiyo, Lundgren, Jens D, Bansi-Matharu, Loveleen, Mabugu, Travor, Sculpher, Mark, Garnett, Geoff, Staprans, Silvija, Becker, Stephen, Murungu, Joseph, Lewin, Sharon R, Deeks, Steven G, and Hallett, Timothy B

Subjects
Biomedical and Clinical Sciences, Public Health, Health Sciences, Immunology, Medical Microbiology, Infectious Diseases, Clinical Research, HIV/AIDS, Comparative Effectiveness Research, Clinical Trials and Supportive Activities, Cost Effectiveness Research, Infection, Good Health and Well Being, Adolescent, Adult, Aged, Anti-HIV Agents, Cost-Benefit Analysis, Female, Forecasting, HIV Infections, Humans, Incidence, Male, Middle Aged, Models, Theoretical, Poverty, Young Adult, Zimbabwe, HIV, cure, economic evaluation, model, antiretroviral therapy, Biological Sciences, Medical and Health Sciences, Microbiology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundIt is unknown what properties would be required to make an intervention in low income countries that can eradicate or control human immunodeficiency virus (HIV) without antiretroviral therapy (ART) cost-effective.MethodsWe used a model of HIV and ART to investigate the effect of introducing an ART-free viral suppression intervention in 2022 using Zimbabwe as an example country. We assumed that the intervention (cost: $500) would be accessible for 90% of the population, be given to those receiving effective ART, have sufficient efficacy to allow ART interruption in 95%, with a rate of viral rebound of 5% per year in the first 3 months, and a 50% decline in rate with each successive year.ResultsAn ART-free viral suppression intervention with these properties would result in >0.53 million disability-adjusted-life-years averted over 2022-2042, with a reduction in HIV program costs of $300 million (8.7% saving). An intervention of this efficacy costing anything up to $1400 is likely to be cost-effective in this setting.ConclusionsInterventions aimed at curing HIV infection have the potential to improve overall disease burden and to reduce costs. Given the effectiveness and cost of ART, such interventions would have to be inexpensive and highly effective.

Published
2016

33. Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz + tenofovir + emtricitabine for HIV

Author

Stirrup, Oliver T., Sabin, Caroline A., Phillips, Andrew N., Williams, Ian, Churchill, Duncan, Tostevin, Anna, Hill, Teresa, Dunn, David T., Asboe, David, Pozniak, Anton, Cane, Patricia, Chadwick, David, Clark, Duncan, Collins, Simon, Delpech, Valerie, Douthwaite, Samuel, Dunn, David, Fearnhill, Esther, Porter, Kholoud, Stirrup, Oliver, Fraser, Christophe, Geretti, Anna Maria, Gunson, Rory, Hale, Antony, Hué, Stéphane, Lazarus, Linda, Leigh-Brown, Andrew, Mbisa, Tamyo, Mackie, Nicola, Orkin, Chloe, Nastouli, Eleni, Pillay, Deenan, Phillips, Andrew, Sabin, Caroline, Smit, Erasmus, Templeton, Kate, Tilston, Peter, Volz, Erik, Zhang, Hongyi, Fairbrother, Keith, Dawkins, Justine, O’Shea, Siobhan, Mullen, Jane, Cox, Alison, Tandy, Richard, Fawcett, Tracy, Hopkins, Mark, Booth, Clare, Renwick, Lynne, Schmid, Matthias L., Payne, Brendan, Hubb, Jonathan, Dustan, Simon, Kirk, Stuart, Bradley-Stewart, Amanda, Jose, Sophie, Thornton, Alicia, Huntington, Susie, Glabay, Adam, Shidfar, Shaadi, Lynch, Janet, Hand, James, de Souza, Carl, Perry, Nicky, Tilbury, Stuart, Youssef, Elaney, Gazzard, Brian, Nelson, Mark, Mabika, Tracey, Mandalia, Sundhiya, Anderson, Jane, Munshi, Sajid, Post, Frank, Adefisan, Ade, Taylor, Chris, Gleisner, Zachary, Ibrahim, Fowzia, Campbell, Lucy, Baillie, Kirsty, Gilson, Richard, Brima, Nataliya, Ainsworth, Jonathan, Schwenk, Achim, Miller, Sheila, Wood, Chris, Johnson, Margaret, Youle, Mike, Lampe, Fiona, Smith, Colette, Tsintas, Rob, Chaloner, Clinton, Hutchinson, Samantha, Walsh, John, Mackie, Nicky, Winston, Alan, Weber, Jonathan, Ramzan, Farhan, Carder, Mark, Leen, Clifford, Wilson, Alan, Morris, Sheila, Gompels, Mark, Allan, Sue, Palfreeman, Adrian, Lewszuk, Adam, Kegg, Stephen, Faleye, Akin, Ogunbiyi, Victoria, Mitchell, Sue, Hay, Phillip, Kemble, Christian, Martin, Fabiola, Russell-Sharpe, Sarah, Gravely, Janet, Allan, Sris, Harte, Andrew, Tariq, Anjum, Spencer, Hazel, Jones, Ron, Pritchard, Jillian, Cumming, Shirley, Atkinson, Claire, Mital, Dushyant, Edgell, Veronica, Allen, Juli, Ustianowski, Andy, Murphy, Cynthia, Gunder, Ilise, Trevelion, Roy, and Babiker, Abdel

Published
2019
Full Text
View/download PDF

34. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Author

Coll, Pep, Cobarsi, Patricia, Nieto, Aroa, Meulbroek, Michael, Carrillo, Antonia, Saz, Jorge, Guerrero, Jorge D.R., García, Mar Vera, Gutiérrez, Felix, Masiá, Mar, Robledano, Catalina, Leon, Agathe, Leal, Lorna, Redondo, Eva G., Estrada, Vicente P., Marquez, Rocio, Sandoval, Raquel, Viciana, Pompeyo, Espinosa, Nuria, Lopez-Cortes, Luis, Podzamczer, Daniel, Tiraboschi, Juan, Morenilla, Sandra, Antela, Antonio, Losada, Elena, Nwokolo, Nneka, Sewell, Janey, Clarke, Amanda, Kirk, Sarah, Knott, Alyson, Rodger, Alison J, Fernandez, Thomas, Gompels, Mark, Jennings, Louise, Ward, Lana, Fox, Julie, Lwanga, Julianne, Lee, Ming, Gilson, Richard, Leen, Clifford, Morris, Sheila, Clutterbuck, Dan, Brady, Michael, Asboe, David, Fedele, Serge, Fidler, Sarah, Brockmeyer, Norbert, Potthoff, Anja, Skaletz-Rorowski, Adriane, Bogner, Johannes, Seybold, Ulrich, Roider, Julia, Jessen, Heiko, Jessen, Arne, Ruzicic, Slobodan, Stellbrink, Hans-Jürgen, Kümmerle, Tim, Lehmann, Clara, Degen, Olaf, Bartel, Sindy, Hüfner, Anja, Rockstroh, Jürgen, Mohrmann, Karina, Boesecke, Christoph, Krznaric, Ivanka, Ingiliz, Patrick, Weber, Rainer, Grube, Christina, Braun, Dominique, Günthard, Huldrych, Wandeler, Gilles, Furrer, Hansjakob, Rauch, Andri, Vernazza, Pietro, Schmid, Patrick, Rasi, Manuela, Borso, Denise, Stratmann, Markus, Caviezel, Oliver, Stoeckle, Marcel, Battegay, Manuel, Tarr, Philip, Christinet, Vanessa, Jouinot, Florent, Isambert, Camille, Bernasconi, Enos, Bernasconi, Beatrice, Gerstoft, Jan, Jensen, Lene P., Bayer, Anne A., Ostergaard, Lars, Yehdego, Yordanos, Bach, Ann, Handberg, Pia, Kronborg, Gitte, Pedersen, Svend s., Bülow, Nete, Ramskover, Bente, Ristola, Matti, Debnam, Outi, Sutinen, Jussi, Blaxhult, Anders, Ask, Ronnie, Hildingsson-Lundh, Bernt, Westling, Katarina, Frisen, Eeva-Maija, Cortney, Gráinne, O'Dea, Siobhan, De Wit, Stephane, Necsoi, Coca, Vandekerckhove, Linos, Goffard, Jean-Christophe, Henrard, Sophie, Prins, Jan, Nobel, Hans-Henrik, Weijsenfeld, Annouschka, Van Eeden, Arne, Elsenburg, Loek, Brinkman, Kees, Vos, Danielle, Hoijenga, Imke, Gisolf, Elisabeth, Van Bentum, Petra, Verhagen, Dominique, Raffi, Francois, Billaud, Eric, Ohayon, Michel, Gosset, Daniel, Fior, Alexandre, Pialoux, Gilles, Thibaut, Pelagie, Chas, Julie, Leclercq, Vincent, Pechenot, Vincent, Coquelin, Vincent, Pradier, Christian, Breaud, Sophie, Touzeau-Romer, Veronique, Rieger, Armin, Kitchen - Maria Geit, Maria, Sarcletti, Mario, Gisinger, Martin, Oellinger, Angela, Antinori, Andrea, Menichetti, Samanta, Bini, Teresa, Mussini, Cristina, Meschiari, Marianna, Di Biagio, Antonio, Taramasso, Lucia, Celesia, Benedetto M., Gussio, Maria, Janeiro, Nuno, Cambiano, Valentina, Bruun, Tina, Collins, Simon, Corbelli, Giulio Maria, Estrada, Vicente, Geretti, Anna Maria, Beloukas, Apostolos, Raben, Dorthe, Prins, Jan M, Brockmeyer, Norbert H, del Romero Guerrero, Jorge, Bogner, Johannes R, Kitchen, Maria, Phillips, Andrew N, and Lundgren, Jens

Published
2019
Full Text
View/download PDF

35. The HIV response beyond 2030: preparing for decades of sustained HIV epidemic control in eastern and southern Africa

Author

Akullian, Adam, Akulu, Ruth, Aliyu, Gambo, Anam, Florence, Guichard, Anne-Claire, Ayles, Helen, Baggaley, Rachel, Bansi-Matharu, Loveleen, Baptiste, Solange L., Bershteyn, Anna, Cambiano, Valentina, Carter, Austin, Chotun, Nafiisah, Citron, Daniel T., Crowley, Siobhan, Dalal, Shona, Edun, Olanrewaju, Fraser, Christophe, Galvani, Alison P., Garnett, Geoffrey P, Glabius, Robert, Godfrey-Faussett, Peter, Grabowski, M. Kate, Gray, Glenda E., Hargreaves, James R., Imai-Eaton, Jeffrey W., Johnson, Leigh F., Kaftan, David, Kagaayi, Joseph, Kataika, Edward, Kilonzo, Nduku, Kirungi, Wilford L., Korenromp, Eline L., Kouton, Mach-Houd, Lucie Abeler-Dörner, Lucie, Mahy, Mary, Mangal, Tara D., Martin-Hughes, Rowan, Matsikure, Samuel, Meyer-Rath, Gesine, Mishra, Sharmistha, Mmelesi, Mpho, Mohammed, Abdulaziz, Moolla, Haroon, Morrison, Michelle R., Moyo, Sikhulile, Mudimu, Edinah, Mugabe, Mbulawa, Murenga, Maurine, Ng'ang'a, Joyce, Olaifa, Yewande, Phillips, Andrew N., Pickles, Michael R.E.H., Probert, William J.M., Ramaabya, Dinah, Rautenbach, Stefan P., Revill, Paul, Shakarishvili, Ani, Sheneberger, Robert, Smith, Jennifer, Stegling, Christine, Stover, John, Tanser, Frank, Taramusi, Isaac, ten Brink, Debra, Whittles, Lilith K., and Zaidi, Irum

Published
2024
Full Text
View/download PDF

36. The changes in health service utilisation in Malawi during the COVID-19 pandemic

Author

She, Bingling, primary, Mangal, Tara D., additional, Adjabeng, Anna Y., additional, Colbourn, Tim, additional, Collins, Joseph H., additional, Janoušková, Eva, additional, Li Lin, Ines, additional, Mnjowe, Emmanuel, additional, Mohan, Sakshi, additional, Molaro, Margherita, additional, Phillips, Andrew N., additional, Revill, Paul, additional, Smith, Robert Manning, additional, Twea, Pakwanja D., additional, Nkhoma, Dominic, additional, Manthalu, Gerald, additional, and Hallett, Timothy B., additional

Published
2024
Full Text
View/download PDF

37. A Healthcare Service Delivery and Epidemiological Model for Investigating Resource Allocation for Health: TheThanzi La OnseModel

Author

Hallett, Timothy B., primary, Mangal, Tara D., additional, Tamuri, Asif U., additional, Arinaminpathy, Nimalan, additional, Cambiano, Valentina, additional, Chalkley, Martin, additional, Collins, Joseph H., additional, Cooper, Jonathan, additional, Gillman, Matthew S., additional, Giordano, Mosè, additional, Graham, Matthew M., additional, Graham, William, additional, Janoušková, Eva, additional, Jewell, Britta L., additional, Lin, Ines Li, additional, Smith, Robert Manning, additional, Manthalu, Gerald, additional, Mnjowe, Emmanuel, additional, Mohan, Sakshi, additional, Molaro, Margherita, additional, Ng’ambi, Wingston, additional, Nkhoma, Dominic, additional, Piatek, Stefan, additional, Revill, Paul, additional, Rodger, Alison, additional, Salmanidou, Dimitra, additional, She, Bingling, additional, Smit, Mikaela, additional, Twea, Pakwanja D., additional, Colbourn, Tim, additional, Mfutso-Bengo, Joseph, additional, and Phillips, Andrew N., additional

Published
2024
Full Text
View/download PDF

38. Markers of inflammation and activation of coagulation are associated with anaemia in antiretroviral-treated HIV disease

Author

Borges, Álvaro H, Weitz, Jeffrey I, Collins, Gary, Baker, Jason V, Lévy, Yves, Davey, Richard T, Phillips, Andrew N, Neaton, James D, Lundgren, Jens D, and Deeks, Steven G

Subjects
HIV/AIDS, Infectious Diseases, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Infection, Good Health and Well Being, Adult, Anemia, Anti-Retroviral Agents, Blood Coagulation Disorders, C-Reactive Protein, CD4 Lymphocyte Count, Cross-Sectional Studies, Female, Fibrin Fibrinogen Degradation Products, HIV Infections, Hemoglobins, Humans, Inflammation, Interleukin-6, Male, Plasma, Viral Load, anaemia, coagulation, C-reactive protein, D-dimer, HIV, interleukin-6, inflammation, INSIGHT SILCAAT Scientific Committee, Biological Sciences, Medical and Health Sciences, Psychology and Cognitive Sciences, Virology
Abstract

ObjectiveThe objective of this study is to determine the relationship between inflammatory interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP)] and coagulation (D-dimer) biomarkers and the presence and type of anaemia among HIV-positive individuals.DesignA cross-sectional study.MethodsCombination antiretroviral therapy (cART)-treated adults participating in an international HIV trial with haemoglobin and mean corpuscular volume (MCV) measurements at entry were categorized by presence of anaemia (haemoglobin ≤14 g/dl in men and ≤12 g/dl in women) and, for those with anaemia, by type [microcytic (MCV 100 fl)]. We analysed the association between inflammation (IL-6 and hsCRP) and coagulation (D-dimer) and haemoglobin, controlling for demographics (age, race and sex), BMI, HIV plasma RNA levels, CD4⁺ T-cell counts (nadir and baseline), Karnofsky score, previous AIDS diagnosis, hepatitis B/C coinfection and use of zidovudine.ResultsAmong 1410 participants, 313 (22.2%) had anaemia. Of these, 4.1, 27.2 and 68.7% had microcytic, normocytic and macrocytic anaemia, respectively. When compared with participants with normal haemoglobin values, those with anaemia were more likely to be older, black, male and on zidovudine. They also had lower baseline CD4⁺ T-cell counts and lower Karnofsky scores. Adjusted relative odds of anaemia per two-fold higher biomarker levels were 1.22 (P = 0.007) for IL-6, 0.99 for hsCRP (P = 0.86) and 1.35 (P

Published
2014

39. Behaviour changes following HIV diagnosis among men who have sex with men in the era of treatment as prevention: data from a prospective study.

Author

Hanum, Nadia, Cambiano, Valentina, Loncar, Dejan, Mandalia, Sundhiya, Sharp, Alice, Lwanga, Julianne, Tiraboschi, Juan, Phillips, Andrew N., Lampe, Fiona C., Beck, Eduard J., and Fox, Julie

Subjects
DIAGNOSIS of HIV infections, LIFESTYLES, RISK-taking behavior, HEALTH status indicators, HUMAN sexuality, SCIENTIFIC observation, LOGISTIC regression analysis, BEHAVIOR, DESCRIPTIVE statistics, MEN who have sex with men, SEX customs, LONGITUDINAL method, ODDS ratio, DATA analysis software, CONFIDENCE intervals, SOCIODEMOGRAPHIC factors, SOCIAL support
Abstract

We described the longitudinal changes in sexual behaviour and associated factors among newly diagnosed with HIV men who have sex with men participating in a prospective observational study from a London HIV clinic (2015–2018). Participants self-completed questionnaires at baseline, months 3 and 12. Information collected included socio-demographic, sexual behaviour, health, lifestyle and social support. Trends in sexual behaviours over one year following diagnosis and associated factors were assessed using generalized estimating equations with logit link. Condomless sex (CLS) dropped from 62.2% at baseline to 47.6% at month-three but increased again to 61.8% at month-12 (p-trend = 0.790). Serodiscordant-CLS increased between month-three and month-12 (from 13.1% to 35.6%, p-trend < 0.001). The prevalence of serodiscordant-CLS with high risk of transmitting to their partners at month-three was 10.7%. CLS was higher among men who reported recreational drug use (adjusted Odds Ratio (aOR) 3.03, 95%CI 1.47–6.24, p = 0.003), those with undetectable viral load (aOR 2.17, 95%CI 1.22-3.84, p = 0.008) and those who agreed with a statement "condoms are not necessary when HIV viral load is undetectable" (aOR 3.41, 95%CI 1.58–7.38, p = 0.002). MSM continued to engage in CLS after HIV diagnosis, which coincided with U = U publications and increased throughout the study. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

Author

Castillo-Mancilla, Jose R., Phillips, Andrew N., Neaton, James D., Neuhaus, Jacqueline, Sharma, Shweta, Baker, Jason V., Collins, Simon, Mannheimer, Sharon, Pett, Sarah, Touzeau-Romer, Veronique, Polizzotto, Mark N., Lundgren, Jens D., and Gardner, Edward M.

Subjects
Efavirenz -- Health aspects -- Analysis, Interleukins -- Health aspects -- Analysis, Highly active antiretroviral therapy -- Health aspects -- Analysis, HIV infections -- Health aspects -- Analysis, Inflammation -- Health aspects -- Analysis, C-reactive protein -- Health aspects -- Analysis, Infection -- Health aspects -- Analysis, Biological products industry -- Health aspects -- Analysis, T cells -- Health aspects -- Analysis, Health
Abstract

Introduction: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study. Methods: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the [CD4.sup.+]/[CD8.sup.+] T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-naive participants with HIV and CD4+ T-cells >500 cells/[mm.sup.3] enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression ( Results: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/[mm.sup.3]. Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed. Conclusions: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048. Keywords: adherence; inflammation; antiretroviral therapy; inteleukin-6; serum amyloid A protein; START study, 1 INTRODUCTION People living with HIV (PLHIV) continue to benefit from antiretroviral therapy (ART) by preventing progression to AIDS [1,2] and transmission to their partners [3]. However, even in the [...]

Published
2019
Full Text
View/download PDF

48. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial

Author

Brown, Samuel M, primary, Barkauskas, Christina E, additional, Grund, Birgit, additional, Sharma, Shweta, additional, Phillips, Andrew N, additional, Leither, Lindsay, additional, Peltan, Ithan D, additional, Lanspa, Michael, additional, Gilstrap, Daniel L, additional, Mourad, Ahmad, additional, Lane, Kathleen, additional, Beitler, Jeremy R, additional, Serra, Alexis L, additional, Garcia, Ivan, additional, Almasri, Eyad, additional, Fayed, Mohamed, additional, Hubel, Kinsley, additional, Harris, Estelle S, additional, Middleton, Elizabeth A, additional, Barrios, Macy A G, additional, Mathews, Kusum S, additional, Goel, Neha N, additional, Acquah, Samuel, additional, Mosier, Jarrod, additional, Hypes, Cameron, additional, Salvagio Campbell, Elizabeth, additional, Khan, Akram, additional, Hough, Catherine L, additional, Wilson, Jennifer G, additional, Levitt, Joseph E, additional, Duggal, Abhijit, additional, Dugar, Siddharth, additional, Goodwin, Andrew J, additional, Terry, Charles, additional, Chen, Peter, additional, Torbati, Sam, additional, Iyer, Nithya, additional, Sandkovsky, Uriel S, additional, Johnson, Nicholas J, additional, Robinson, Bryce R H, additional, Matthay, Michael A, additional, Aggarwal, Neil R, additional, Douglas, Ivor S, additional, Casey, Jonathan D, additional, Hache-Marliere, Manuel, additional, Georges Youssef, J, additional, Nkemdirim, William, additional, Leshnower, Brad, additional, Awan, Omar, additional, Pannu, Sonal, additional, O'Mahony, Darragh Shane, additional, Manian, Prasad, additional, Awori Hayanga, J W, additional, Wortmann, Glenn W, additional, Tomazini, Bruno M, additional, Miller, Robert F, additional, Jensen, Jens-Ulrik, additional, Murray, Daniel D, additional, Bickell, Nina A, additional, Zatakia, Jigna, additional, Burris, Sarah, additional, Higgs, Elizabeth S, additional, Natarajan, Ven, additional, Dewar, Robin L, additional, Schechner, Adam, additional, Kang, Nayon, additional, Arenas-Pinto, Alejandro, additional, Hudson, Fleur, additional, Ginde, Adit A, additional, Self, Wesley H, additional, Rogers, Angela J, additional, Oldmixon, Cathryn F, additional, Morin, Haley, additional, Sanchez, Adriana, additional, Weintrob, Amy C, additional, Cavalcanti, Alexandre Biasi, additional, Davis-Karim, Anne, additional, Engen, Nicole, additional, Denning, Eileen, additional, Taylor Thompson, B, additional, Gelijns, Annetine C, additional, Kan, Virginia, additional, Davey, Victoria J, additional, Lundgren, Jens D, additional, Babiker, Abdel G, additional, Neaton, James D, additional, Lane, H Clifford, additional, Tierney, John, additional, Vogel, Susan E., additional, McNay, Laura A., additional, Cahill, Kelly, additional, Crew, Page, additional, Sardana, Ratna, additional, Segal Raim, Sharo, additional, Shaw-Saliba, Katy, additional, Atri, Negin, additional, Miller, Mark, additional, Vallee, David, additional, Chung, Lucy, additional, Delph, Yvette, additional, Adam, Stacey J., additional, Read, Sarah, additional, Draghia-Akli, Ruxandra, additional, Harrigan, Rachel, additional, Carlsen, Amy, additional, Carter, Anita, additional, DuChene, Alain, additional, Eckroth, Kate, additional, Frase, Alex, additional, Harrison, Merrie, additional, Meger, Sue, additional, Quan, Kien, additional, Quan, Siu Fun, additional, Reilly, Cavan, additional, Thompson, Greg, additional, Walski, Jamie, additional, Moskowitz, Alan J., additional, Bagiella, Emilia, additional, Moquete, Ellen, additional, O'Sullivan, Karen, additional, Marks, Mary E., additional, Accardi, Evan, additional, Kinzel, Emily, additional, Bedoya, Gabriela, additional, Gupta, Lopa, additional, Overbey, Jessica R., additional, Padillia, Maria L., additional, Santos, Milerva, additional, Gillinov, Marc A., additional, Miller, Marissa A., additional, Taddei-Peters, Wendy C., additional, Fenton, Kathleen, additional, Smith, Peter K., additional, Vekstein, Andrew M., additional, Ko, Emily R., additional, Al-Hegelan, Mashael S., additional, McGowan, Lauren M., additional, Motta, Mary, additional, Howell, Shauna, additional, Bent, Francine, additional, Kalager, Rachel, additional, Chan, Emmanuel, additional, Aloor, Heather L., additional, Griffin, S. Michelle, additional, Covington, Anna, additional, McLendon-Arvik, Beth, additional, Bussadori, Barbara, additional, Miller-Bell, Mary, additional, Sampey, Cathy, additional, Gaver, Vincent, additional, Hollister, Beth A., additional, Giangiacomo, Dana M., additional, Pauley, Alena, additional, Patel, Aashay, additional, Classon, Chris, additional, Frazier, Madison, additional, Osborne, Robyn, additional, Conlon, Debbi H., additional, Joshi, Marybeth, additional, Gottlieb, Robert L., additional, Mack, Michael, additional, Berhe, Mezgebe, additional, Haley, Clinton, additional, Dishner, Emma, additional, Bettacchi, Christopher, additional, Golden, Kevin, additional, Duhaime, Erin, additional, Ryan, Madison, additional, Tallmadge, Catherine, additional, Estrada, Lorie, additional, Jones, Felecia, additional, Villa, Samantha, additional, Wang, Samantha, additional, Robert, Raven, additional, Coleman, Tanquinisha, additional, Clariday, Laura, additional, Baker, Rebecca, additional, Hurutado-Rodriguez, Mariana, additional, Iram, Nazia, additional, Fresnedo, Michelle, additional, Davis, Allyson, additional, Leonard, Kiara, additional, Ramierez, Noelia, additional, Thammavong, Jon, additional, Duque, Krizia, additional, Turner, Emma, additional, Fisher, Tammy, additional, Robinson, Dianna, additional, Ransom, Desirae, additional, Maldonado, Nicholas, additional, Lusk, Erica, additional, Killian, Aaron, additional, Palacios, Adriana, additional, Solis, Edilia, additional, Jerrow, Janet, additional, Watts, Matthew, additional, Whitacre, Heather, additional, Cothran, Elizabeth, additional, Bender, William, additional, Miller, Jeffrey, additional, Nugent, Katherine, additional, Farrington, Woodrow, additional, Baio, Kim T., additional, McBride, Mary K., additional, Fielding, Michele, additional, Mathewson, Sonya, additional, Porte, Kristina, additional, Haley, Elizabeth, additional, Rogers, Susan, additional, Tyler, Derrick, additional, Perin, Emerson, additional, Costello, Briana, additional, Postalian, Alexander, additional, Sohail, Rizwan, additional, Hinsu, Punit, additional, Watson, Carolyn, additional, Kappenman, Casey, additional, Chen, James, additional, Walker, Kim, additional, Fink, Melyssa, additional, Phillip, Gabrielle, additional, Mahon, Kim, additional, Sturgis, Lydia, additional, Maher, Patrick, additional, Rogers, Linda, additional, Ng, Nicole, additional, Marshall, Jason, additional, Bassily-Marcus, Adel, additional, Cohen, Ivy, additional, Ramoo, Shamini, additional, Malhotra, Aryan, additional, Kessler, Jonathan, additional, Goetz, Rebekah, additional, Badhwar, Vinay, additional, Hayanga, Jeremiah, additional, Giblin Sutton, Lisa, additional, Williams, Roger, additional, Berry Bartolo, Elizabeth, additional, Walker, Dmitry, additional, Bunner, Robin, additional, Glaze, Chad, additional, Aucremanne, Tanja, additional, Bishop, James, additional, Kelley, Macey, additional, Peterson, Autumn, additional, Sauerborn, Erica, additional, Reckart, Robin, additional, Miller, Brittany, additional, Mittel, Aaron, additional, Darmanian, Anita, additional, Rosen, Amanda, additional, Madahar, Purnema, additional, Schicchi, John, additional, Gosek, Katarzyna, additional, Dzierba, Amy, additional, Wahab, Romina, additional, Eng, Connie, additional, Al-Saadi, Mukhtar, additional, Zahiruddin, Faisal, additional, Syed, Mohi, additional, George, Michael, additional, Patel, Varsha, additional, Onwunyi, Chisom, additional, Barroso da Costa, Rosa, additional, North, Crystal, additional, Ringwood, Nancy, additional, Fitzgerald, Laura, additional, Muzikansky, Ariela, additional, Morse, Richard, additional, Brower, Roy G., additional, Reineck, Lora A., additional, Bienstock, Karen, additional, Hou, Peter, additional, Steingrub, Jay S., additional, Tidswell, Mark A., additional, Kozikowski, Lori-Ann, additional, Kardos, Cynthia, additional, De Souza, Leslie, additional, Talmor, Daniel, additional, Shapiro, Nathan, additional, Hibbert, Kathryn, additional, Brait, Kelsey, additional, Kone, Mamary, additional, Hendey, Gregory, additional, Kangelaris, Kirsten N., additional, Ashktorab, Kimia, additional, Gropper, Rachel, additional, Agrawal, Anika, additional, Timothy, Kelly, additional, Zhou, Hanjing, additional, Hughes, Alyssa, additional, Garcia, Rebekah, additional, Torres, Adrian, additional, Hernandez-Almaraz, Maria Elena, additional, Vojnik, Rosemary, additional, Perez, Cynthia, additional, McDowell, Jordan, additional, Chang, Steven Y., additional, Vargas, Julia, additional, Moss, Marc, additional, McKeehan, Jeffrey, additional, Higgins, Carrie, additional, Johnson, Emily, additional, Slaughter, Suzanne, additional, Wyles, David, additional, Hiller, Terra, additional, Oakes, Judy, additional, Garcia, Ana, additional, Gravitz, Stephanie, additional, Lyle, Carolynn, additional, Swanson, Diandra, additional, Gong, Michelle Ng., additional, Richardson, Lynnne D., additional, Chen, Jen-Ting, additional, Moskowitz, Ari, additional, Mohamed, Amira, additional, Lopez, Brenda, additional, Amosu, Omowunmi, additional, Tzehaie, Hiwet, additional, Boujid, Sabah, additional, Bixby, Billie, additional, Lopez, Anitza A., additional, Durley, JaVon, additional, Gilson, Boris, additional, Hite, R. Duncan, additional, Wang, Henry, additional, Wiedemann, Hebert P., additional, Mehkri, Omar, additional, Ashok, Kiran, additional, King, Alexander, additional, Brennan, Connery, additional, Exline, Matthew C., additional, Englert, Joshua A., additional, Karow, Sarah, additional, Schwartz, Elizabeth, additional, So, Preston, additional, So, Madison, additional, Krol, Olivia F., additional, Briceno Parra, Genesis I., additional, Mills, Emmanuel Nii Lantei, additional, Oh, Minn, additional, Pena, Jose, additional, Martínez, Jesús Alejandro, additional, Jackman, Susan E., additional, Bayoumi, Emad, additional, Pascual, Ethan, additional, Caudill, Antonina, additional, Chen, Po-En, additional, Richardson, Tabia, additional, Clapham, Gregg J., additional, Herrera, Lisa, additional, Ojukwu, Cristabelle, additional, Fine, Devin, additional, Gomez, Millie J., additional, Choi-Kuaea, Yunhee, additional, Weissberg, Gwendolyn, additional, Isip, Katherine, additional, Mattison, Brittany, additional, Tran, Dana, additional, Emilov Dukov, Jennifer, additional, Chung, Paul, additional, Kang, Bo Ran, additional, Escobar, Lauren, additional, Tran, Trung, additional, Baig, Saba, additional, Wallick, Julie A., additional, Duven, Alexandria M., additional, Fletcher, Dakota D., additional, Gundel, Stephanie, additional, Fuentes, Megan, additional, Newton, Maranda, additional, Peterson, Emily, additional, Jiang, Kelsey, additional, Files, D. Clark, additional, Miller, Chadwick, additional, Lematty, Caitlin, additional, Rasberry, April, additional, Warden, Ashley, additional, Bledsoe, Joseph, additional, Knowlton, Kirk, additional, Knox, Daniel B., additional, Klippel, Carolyn, additional, Armbruster, Brent P., additional, Applegate, Darrin, additional, Imel, Karah, additional, Fergus, Melissa, additional, Rahmati, Kasra, additional, Jensen, Hannah, additional, Aston, Valerie T., additional, Jeppson, Joshua, additional, Marshall, J. Hunter, additional, Lumpkin, Jenna, additional, Smith, Cassie, additional, Burke, Tyler, additional, Gray, Andrew, additional, Paine, Robert, additional, Callahan, Sean, additional, Yamane, Misty, additional, Waddoups, Lindsey, additional, Rice, Todd W., additional, Johnson, Jakea, additional, Gray, Christopher, additional, Hays, Margaret, additional, Roth, Megan, additional, Musick, Sarah, additional, Miller, Karen, additional, Semler, Matthew W., additional, Popielski, Laura, additional, Kambo, Amy, additional, Viens, Kimberly, additional, Turner, Melissa, additional, Vjecha, Michael J., additional, Denyer, Rachel, additional, Khosla, Rahul, additional, Rajendran, Bindu, additional, Gonzales, Melissa, additional, Moriarty, Theresa, additional, Biswas, Kousick, additional, Harrington, Cristin, additional, Garcia, Amanda, additional, Bremer, Tammy, additional, Burke, Tara, additional, Koker, Brittany, additional, Pittman, David, additional, Vasudeva, Shikha S., additional, Anholm, James D., additional, Specht, Lennard, additional, Rodriguez, Aimee, additional, Ngo, Han, additional, Duong, Lien, additional, Previte, Matthew, additional, Raben, Dorthe, additional, Nielsen, Charlotte B., additional, Friis Larsen, Jakob, additional, Peters, Lars, additional, Matthews, Gail, additional, Kelleher, Anthony, additional, Polizzotto, Mark, additional, Carey, Catherine, additional, Chang, Christina, additional, Dharan, Nila, additional, Hough, Sally, additional, Virachit, Sophie, additional, Davidson, Sarah, additional, Bice, Daniel J., additional, Ognenovska, Katherine, additional, Cabrera, Gesalit, additional, Flynn, Ruth, additional, Abdelghany, Mazin, additional, Baseler, Beth, additional, Teitelbaum, Marc, additional, Holley, H. Preston, additional, Jankelevich, Shirley, additional, Adams, Amy, additional, Becker, Nancy, additional, Doleny, Suzanne, additional, Hissey, Debbie, additional, Simpson, Shelly, additional, Kim, Mi Ha, additional, Beeler, Joy, additional, Harmon, Liam, additional, Vanderpuye, Sharon, additional, Yeon, Lindsey, additional, Frye, Leanna, additional, Rudzinski, Erin, additional, Buehn, Molly, additional, Eccard-Koons, Vanessa, additional, Frary, Sadie, additional, MacDonalad, Leah, additional, Cash, Jennifer, additional, Hoopengardner, Lisa, additional, Linton, Jessica, additional, Nelson, Michaela, additional, Spinelli-Nadzam, Mary, additional, Proffitt, Calvin, additional, Lee, Christopher, additional, Engel, Theresa, additional, Fontaine, Laura, additional, Osborne, CK, additional, Hohn, Matt, additional, Galcik, Michael, additional, Thompson, DeeDee, additional, Sandrus, Jen, additional, Manchard, Jon, additional, Giri, Jiwan, additional, Kopka, Stacy, additional, Chang, Weizhong, additional, Sherman, Brad T., additional, Rupert, Adam W., additional, Highbarger, Helene, additional, Baseler, Michael, additional, Lallemand, Perrine, additional, Rehman, Tauseef, additional, Imamichi, Tom, additional, Laverdure, Sylvain, additional, Paudel, Sharada, additional, Cook, Kyndal, additional, Haupt, Kendra, additional, Hazen, Allison, additional, Badralmaa, Yunden, additional, Highbarger, Jeroen, additional, McCormack, Ashley, additional, Gerry, Norman P., additional, Smith, Kenneth, additional, Patel, Bhakti, additional, Domeraski, Nadia, additional, Hoover, Marie L., additional, DuChateau, Nadine, additional, Flosi, Adam, additional, Nelson, Rich, additional, Stojanovic, Jelena, additional, and Wenner, Christine, additional

Published
2023
Full Text
View/download PDF

50. Understanding experiences of potential harm among MSM (cis and trans) using HIV self-testing in the SELPHI randomised controlled trial in England and Wales: a mixed-methods study

Author

Witzel, T Charles, primary, Nicholls, Emily Jay, additional, McCabe, Leanne, additional, Weatherburn, Peter, additional, McCormack, Sheena, additional, Bonell, Christopher, additional, Gafos, Mitzy, additional, Lampe, Fiona C, additional, Speakman, Andrew, additional, Dunn, David, additional, Ward, Denise, additional, Phillips, Andrew N, additional, Pebody, Roger, additional, Gabriel, Michelle M, additional, Collaco-Moraes, Yolanda, additional, Rodger, Alison J, additional, and Burns, Fiona M, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results